## JBL: Jabil Inc. - XLK: Technology

### Executive Summary

STRENGTH thesis confirmed: MRS_10 at 5.9% in upper entry zone (3.0-6.0%), top 8% cross-sectional ranking. Short-term MRS_5 (2.9%) confirms momentum alignment. Strong momentum (+2.3% 5-day acceleration). Outperforming sector by 4.8%. Caution: overbought RSI (72).

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($218.25)
- **If Wrong:** Exit if MRS_10 drops below entry zone or breaks stop
- **Invalidation:** MRS_10 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 6, Bearish: 0)

**1. Jabil Gets A Price Target Hike As Growth Plans Take Shape**
- Source: Finimize | 20251210T161106 | Bullish | Relevance: 99%
- BofA Securities raised its price target for Jabil to $262, maintaining a buy rating, despite the stock dipping slightly this week. This confidence is attributed to Jabil's long-term growth strategy, which includes new factory expansions in North Carolina and Croatia, strengthening its position in AI-driven projects and the GLP-1 drug market, as well as a potential acquisition. These moves are expected to boost revenue and margins by 2027, showcasing how manufacturing is adapting to technological innovation and strategic acquisitions to secure future demand.

**2. Has Jabilâ€™s 469.9% Five Year Surge Left Any Value on the Table in 2025?**
- Source: Simply Wall Street | 20251209T000815 | Somewhat-Bullish | Relevance: 99%
- Jabil (NYSE: JBL) has seen significant growth, up 469.9% over five years, leading investors to question its current valuation at around $225. A Discounted Cash Flow analysis suggests it's undervalued by 12.8% at $258.47 per share, while its Price-to-Earnings ratio of 36.7x, compared to a calculated 'Fair Ratio' of 31.2x, indicates it might be somewhat overvalued based on its fundamentals. The article suggests using "Narratives" for a personalized valuation, incorporating individual beliefs about the company's future performance.

**3. AI Hardware Leader Rallies Into Buy Zone As Earnings Approach**
- Source: Investor's Business Daily | 20251211T190813 | Bullish | Relevance: 99%
- Jabil (JBL), an artificial intelligence hardware provider, has entered a buy zone as its stock rallies, setting up for its fiscal first-quarter earnings report next week. The company is poised for its eighth consecutive win on Thursday, thrusting Jabil stock into the spotlight of IBD 50 Growth Stocks To Watch. This positive movement comes amid a strong performance and rising composite rating for Jabil.

**4. Jabil Opens Catheter Development Lab**
- Source: PlasticsToday | 20251209T180818 | Bullish | Relevance: 98%
-  Jabil has opened a new Advanced Catheter Development Lab at its St. Petersburg, FL, headquarters to expand its capabilities in minimally invasive medical device technology. The lab will support universities and major healthcare brands in advancing catheter development and will focus on engineering, prototyping, and new product introduction for advanced catheters and other devices. This initiative reflects Jabil's commitment to investments in medical advances that lead to better outcomes for patients.

**5. Jabil Prepares For Key Earnings During AI, Infrastructure Shifts**
- Source: Benzinga | 20251210T180050 | Somewhat-Bullish | Relevance: 98%
-  Jabil Inc. (NYSE: JBL) is facing downward pressure on its stock ahead of its Q1 fiscal year 2026 earnings report, with investors focused on AI demand, new capacity projects, and a recent power-infrastructure deal. BofA Securities reiterated a Buy rating, raising the price target from $255 to $262, anticipating continued strength in AI-related revenue and improved fiscal performance in 2027. The company's acquisition of Hanley Energy and upcoming facility operations are expected to boost future revenue and margins.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-10 | B of A Securiti | $262 | $255 | +3% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-10 | B of A Securiti | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 7 ($0.00M) |
| Sells | 50 ($12.50M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 48.6% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 6 |

**Top Holders:**
- Vanguard Group Inc: 12.3% (-0.1%)
- Blackrock Inc.: 9.0% (+2.1%)
- Texas Yale Capital C: 6.0% (-0.1%)
- State Street Corpora: 4.9% (+0.7%)
- Wellington Managemen: 4.1% (-30.7%)

### Key Risks

1. Heavy insider selling: $13M sold (50 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_10 improving +2.3% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 0.91 indicates undervaluation relative to growth. Quality metrics strong (ROE 40%). Insider selling cluster ($12.5M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 6 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $25.1B |
| Beta | 1.26 |
| 52W Range | $108.66 - $237.14 |
| Short Interest | 4.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.91 |
| Forward P/E | 18.2 |
| Current P/E | 21.1 |
| YoY Growth | 16.0% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from 3.6% to 5.9% (+2.3% in 5 days), confirming momentum buildup. Currently in upper STRENGTH zone (3.0-6.0%), cross-sectional ranking at 91st percentile. MRS_5 at 2.9% confirms short-term momentum alignment. Outperforming sector by 4.8pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (3.19), confirming momentum. RSI overbought at 72, risk of mean reversion.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 5.89% (CS: 92) | Strong |
| RSI_14 | 71.8 | Overbought |
| MACD Histogram | 3.19 | Bullish |
| vs SMA20 | 1.114x | Above |
| vs SMA50 | 1.116x | Above |
| vs SMA200 | 1.235x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $234.25
- **Stop Loss:** $218.25 (6.8% risk)
- **Target:** $258.25 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 86
- **Position Value:** $20,145.50
- **Portfolio %:** 20.15%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX at low 8th percentile signals complacency, but decent breadth and positive yield curve support selective positioning. Focus on quality names with earnings visibility.*

### Earnings

**Next:** 2025-12-17 (Est: $2.72)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.95 | $3.29 | +11.7% |
| 2025Q2 | $2.32 | $2.55 | +9.8% |
| 2025Q1 | $1.83 | $1.94 | +6.2% |
| 2024Q4 | $1.88 | $2.00 | +6.5% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*